Right ventricular failure unresponsive to pharmacologic treatment occurs in approximately 20% to 30% of patients supported with a left ventricular assist device (LVAD). The effect of the assistance on right ventricular function is highly controversial. Increased venous return produced by an LVAD can affect right ventricular function by increasing preload. On the other hand, an LVAD can improve the filling of the right ventricle by unloading the left ventricle, reducing its chamber size and shifting the septum back to the left. Right ventricular function is highly afterload dependent, the ventricular function depending on the pulmonary vascular resistance. With a normal pulmonary vascular bed, the LVAD can improve right ventricular function by reducing right ventricular afterload. If there is a fixed high pulmonary pressure, however, the LVAD can increase right ventricular afterload and volume. We conclude that the right ventricle is dispensable if the pulmonary vascular bed is normal.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/0003-4975(95)01026-2 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Right Ventricular Myocardial Infarction: Pathophysiology, Diagnosis, and Therapeutic Approaches.
Cardiol Rev
January 2025
Departments of Cardiology and Medicine, New York Medical College and Westchester Medical Center, Valhalla, NY.
Right ventricular myocardial infarction (RVMI) is a significant and distinct form of acute myocardial infarction associated with considerable morbidity and mortality. It occurs most commonly due to proximal right coronary artery obstruction, often in conjunction with inferior myocardial infarction. RVMI poses unique diagnostic and therapeutic challenges due to the anatomical and functional differences between the right and left ventricles.
View Article and Find Full Text PDFMicroRNA-221 protects myocardial contractility in myocardial ischemia/reperfusion injury through phospholamban.
PLoS One
January 2025
Department of Pathology, 906 Hospital of Joint Logistic Support Force of PLA, Ningbo, Zhejiang, China.
Objective: To investigate the effects and mechanisms of miRNA 221 on myocardial ischemia/reperfusion injury (MIRI) in mice through the regulation of phospholamban (PLB) expression.
Methods: The MIRI mouse model was created and mice were divided into sham, MIRI, MIRI+ 221, and MIRI+ scr groups, with miRNA 221 overexpression induced in the myocardium of MIRI mice by targeted myocardial injection. Quantitative RT-PCR analysis was performed to observe the variation in miRNA 221, PLB, SERCA2, RYR2, NCX1, Cyt C and caspase 3 mRNA levels in myocardium, while Western blot assessed the levels of PLB, p-PLB (Ser16), p-PLB (Thr17), SERCA2, RYR2, NCX1, Cyt C and caspase 3 proteins.
[Catheter ablation in patients with heart failure-who benefits?].
Herzschrittmacherther Elektrophysiol
January 2025
Klinik für Elektrophysiologie/Rhythmologie, Ruhr-Universität Bochum, Bochum, Deutschland.
Atrial fibrillation (AF) ablation is associated with a lower likelihood of death and surgical heart failure (HF) interventions in patients with HF. This effect is mainly driven by reduced all cause and cardiovascular death following ablation. Ablation also results in improved left ventricular (LV) function, decreased AF burden and AF regression.
View Article and Find Full Text PDFPredictive Value of Left Atrial Strain for Thrombotic Events in Hypertrophic Cardiomyopathy without Atrial Fibrillation.
Radiol Cardiothorac Imaging
February 2025
From the Department of Cardiology (L.P., W.J., J.L., W.Q., Y.X., Y.K., Q.Z., Y.C.), Department of Geriatrics (K.W.), and Center of Rare Diseases (Y.C.), West China Hospital, Sichuan University, No. 37, Guo Xue Road, Chengdu, Sichuan 610041, China; and Wexner Medical Center, College of Medicine, The Ohio State University, Columbus, Ohio (Y.H.).
Purpose To assess the predictive value of left atrial (LA) fast long-axis strain derived from cardiac MRI for thrombotic events (TEs) in individuals with hypertrophic cardiomyopathy (HCM). Materials and Methods This secondary analysis of an ongoing prospective trial (Chinese Clinical Trial Registry: ChiCTR1900024094) included consecutive participants with HCM without atrial fibrillation (AF) who underwent cardiac MRI from January 2012 to December 2020. The LA fast long-axis strain was obtained by semiautomatically tracking the distance between the atrioventricular junction and the midposterior LA wall.
View Article and Find Full Text PDFCardiac sarcoidosis; update for the heart failure specialist.
Curr Opin Cardiol
January 2025
Division of Cardiology, University of Ottawa Heart Institute, University of Ottawa, Faculty of Medicine, Tier 1 Clinical Research Chair in Cardiac Electrophysiology, Ottawa, ON, Canada.
Purpose Of Review: This review presents contemporary data on epidemiology, common presentations, investigations and diagnostic algorithms, treatment and prognosis. It particularly focuses on topics of most relevance to heart failure specialists, including what left ventricle (LV) function changes can be expected after treatment and outcomes to all standard and advanced heart failure therapies.
Recent Findings: Around 5% of sarcoidosis patients have clinically manifest cardiac sarcoidosis (CS), presenting with significant arrhythmias (such as conduction disturbances and ventricular arrhythmias) or newly developed unexplained heart failure.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!